Product sourcing reference

Cagrilintide

Cagrilintide is a long-acting amylin analogue under clinical investigation. Review its investigational status and the exact material before adding it to a request.

Reference variants

Add Cagrilintide to an order request

Quantities are individual vials (packs of 10). Orders need 100 vials and/or 20 spray bottles in total, mixed across items. Prices are reference estimates captured 2026-10-16; every request is pending eligibility and availability review. Per-unit figures are rounded to the cent from kit pricing, so a final quote may differ slightly.

10mgVial · confirm physical formCAS 1415456-99-3

$44.85/vial$35.88/vial at 1,000+ vials of this item

Quantity of Cagrilintide 10mg in vials vials, packs of 10

Review your order request · Compare the full catalog

Confirm the exact substance

Cagrilintide targets amylin receptors rather than the GLP-1 receptor. Treat it as its own molecule with its own regulatory position, not as a substitute for an approved incretin medicine.

What the review will ask

No approved finished product contains cagrilintide alone. A purchasing team should document how the material would be used and who has confirmed that the use is permitted.

State the facility type, destination state and intended transaction. Do not send patient information.
Expect product- and lot-specific documentation to be requested before any material is accepted.
A listed price is a reference estimate. Availability, labeling, shipping and terms are confirmed in writing only after review.

Purchasing questions

Is cagrilintide an approved medicine?

No. It has been studied in clinical trials, including in combination with semaglutide, but trial activity does not create an approved product or a compounding pathway.

Check the restriction before comparing prices

FDA explicitly states that cagrilintide cannot be used in compounding under federal law. Its development as an amylin-related compound does not make it an approved alternative to semaglutide.

Documentation to request

Document the exact material and intended nonclinical inquiry; a reference quote cannot authorize clinical purchasing.

Regulatory context: FDA: unapproved GLP-1 drugs and ingredient restrictions. Source reviewed 2026-10-16. This source does not verify the identity, testing or availability of our catalog references.

Related guidance: Weight-loss clinic sourcing requirements. These references support a review, not a treatment recommendation or supply authorization.

Verify the current regulatory position

Use FDA human drug compounding guidance and applicable state requirements. This reference is not medical or legal advice and does not establish a lawful supply route.

Discuss sourcing requirements